Search results for "INFECTION"

showing 10 items of 3717 documents

SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell …

2021

Syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a second outbreak significantly delaying the hope for the virus’ complete eradication. In the absence of effective vaccines, we need effective treatments with low adverse effects that can treat hospitalized patients with COVID-19 disease. In this study, we determined the existence of SARS-CoV-2-specific T cells within CD45RA– memory T cells in the blood of convalescent donors. Memory T cells can respond quickly to infection and provide long-term immune protection to reduce the severity of COVID-19 symptoms. Also, CD45RA– memory T cells confer protection from other pathogens encountered by the donors throughout their life. It is of vita…

0301 basic medicineCD3Secondary infectionDiseasemedicine.disease_causeVirusCell therapyCell and Developmental Biology03 medical and health sciences0302 clinical medicinememory T cells (Tmem)MedicineAdverse effectlcsh:QH301-705.5Original ResearchCoronavirusbiologybusiness.industryEffectorCOVID-19Cell BiologylymphopeniaBiobankbiobank030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesisImmunologybiology.proteinadoptive cell therapy (ACT)businessCD8Developmental Biology
researchProduct

Analysis of T and NK cell subsets in Sicilian population from young to supercentenarian: the role of age and gender

2021

Summary Ageing dramatically affects number and function of both innate and adaptive arms of immune system, particularly T cell subsets, contributing to reduced vaccination efficacy, decreased resistance to infections and increased prevalence of cancer in older people. In the present paper, we analysed the age‐related changes in the absolute number of lymphocytes in 214 Sicilian subjects, and in the percentages of T and natural killer (NK) cells in a subcohort of donors. We compared these results with the immunophenotype of the oldest living Italian supercentenarian (aged 111 years). The results were also sorted by gender. The correlation between number/percentage of cells and age in all ind…

0301 basic medicineCD4-Positive T-LymphocytesMaleAgingCytomegalovirusCD8-Positive T-LymphocytesSupercentenarian0302 clinical medicineImmunophenotypingT-Lymphocyte SubsetsImmunology and AllergySicilyAged 80 and overeducation.field_of_studyT lymphocyte subsetsAge FactorsCMVGender IdentityMiddle AgedImmunity and AgeingKiller Cells Naturalmedicine.anatomical_structureCytomegalovirus InfectionsOriginal ArticleFemaleAdultNaive T cellT cellImmunologyPopulationCD4-CD8 RatioBiologyImmunophenotyping03 medical and health sciencesImmune systemmedicineHumanseducationAgedSettore MED/04 - Patologia GeneraleCancerGendermedicine.diseaseT Lymphocyte subset030104 developmental biologyAgeingImmunologyORIGINAL ARTICLESCD8030215 immunology
researchProduct

Immunological features of coronavirus disease 2019 in patients with cancer.

2020

Background Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has caused a major pandemic. Patients with cancer are at higher risk of severe COVID-19. We aimed to describe and compare the immunological features of cancer patients hospitalised for COVID-19 or other concomitant, cancer-related illness. Methods In this prospective study, the clinical and immunological characteristics of 11 cancer patients with COVID-19 and 11 non–COVID-19 cancer patients hospitalised in the same unit at the same period for other medical issues were analysed. We also used 10 healthy volunteers as controls. Peripheral immune parameters were analysed using multiparamet…

0301 basic medicineCD4-Positive T-LymphocytesMaleCancer ResearchTime Factors[SDV]Life Sciences [q-bio]Pneumonia ViralHuman leukocyte antigenCD8-Positive T-LymphocytesProcalcitonin03 medical and health sciencesBetacoronavirus0302 clinical medicineImmune systemNeoplasmsMedicineCytotoxic T cellHumansProspective StudiesPandemicsOriginal ResearchCancerAgedbusiness.industrySARS-CoV-2MonocyteCancerCOVID-19medicine.disease3. Good healthImmunomonitoring[SDV] Life Sciences [q-bio]030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunologyTumor necrosis factor alphaFemaleFrancebusinessCoronavirus InfectionsCD8T-Lymphocytes CytotoxicEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis

2021

AbstractThe prophylactic vaccines available to protect against infections by HPV are well tolerated and highly immunogenic. People with HIV have a higher risk of developing HPV infection and HPV-associated cancers due to a lower immune response, and due to viral interactions. We performed a systematic review of RCTs to assess HPV vaccines efficacy and safety on HIV-infected people compared to placebo or no intervention in terms of seroconversion, infections, neoplasms, adverse events, CD4+ T-cell count and HIV viral load. The vaccine-group showed a seroconversion rate close to 100% for each vaccine and a significantly higher level of antibodies against HPV vaccine types, as compared to the …

0301 basic medicineCD4-Positive T-LymphocytesMaleDisease preventionHIV InfectionsAdolescent Adult Antibodies Viral CD4 Lymphocyte Count CD4-Positive T-Lymphocytes Female HIV Infections Humans Male Papillomavirus Infections Papillomavirus Vaccines Public Health Randomized Controlled Trials as Topic Risk Treatment Outcome Viral Load Virus Shedding Young Adult Patient SafetySettore MED/42 - Igiene Generale E ApplicataAntibodies Viral0302 clinical medicine030212 general & internal medicineViralRandomized Controlled Trials as TopicPublic healthMultidisciplinaryQHPV infectionRViral LoadAdolescent; Adult; Antibodies Viral; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; HIV Infections; Humans; Male; Papillomavirus Infections; Papillomavirus Vaccines; Public Health; Randomized Controlled Trials as Topic; Risk; Treatment Outcome; Viral Load; Virus Shedding; Young Adult; Patient SafetyVirus SheddingTreatment OutcomeMedicineFemalePublic HealthPatient SafetyViral loadAdultRiskmedicine.medical_specialtyAdolescentScienceHPV vaccinesPlaceboAntibodiesArticle03 medical and health sciencesPapillomavirus VaccinesYoung AdultInternal medicinemedicineHumansPapillomavirus VaccinesSeroconversionViral sheddingAdverse effectbusiness.industryPapillomavirus InfectionsHealth caremedicine.diseaseCD4 Lymphocyte Count030104 developmental biologybusinessScientific Reports
researchProduct

Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients' Queries, Needs, Fears, and Actions Taken

2020

PURPOSE This descriptive investigation was undertaken at three oncology units to report queries, needs, and fears related to severe acute respiratory syndrome coronavirus 2 (COVID-19) of patients with cancer and to avoid uncontrolled treatment delays or withdrawal, behavioral mistakes, and panic. PATIENTS AND METHODS All queries spontaneously delivered through the WhatsApp instant messaging system commonly used by patients to communicate with oncology units were collected and grouped by homology in five categories. Responses to the queries were given according to recommendations by the Italian Association of Medical Oncology through WhatsApp and by subsequent phone calls. Patients were also…

0301 basic medicineCancer Research2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)WhatsApp messenger cancer patient reactions action taken COVID-19 outbreak sentimental analysisPneumonia ViralMEDLINETime to treatmentTime-to-Treatment03 medical and health sciences0302 clinical medicineNeoplasmsSurveys and QuestionnairesOriginal ReportsPandemicmedicineHumansIntensive care medicinePandemicsText Messagingbusiness.industryCOVID-19CancerFearmedicine.diseasePneumonia030104 developmental biologyOncology030220 oncology & carcinogenesisCoronavirus Infectionsbusiness
researchProduct

Cancer therapy and treatments during COVID-19 era

2020

The COVID-19 pandemic has put a serious strain on health treatments as well at the economies of many nations. Unfortunately, there is not currently available vaccine for SARS-Cov-2/COVID-19. Various types of patients have delayed treatment or even routine check-ups and we are adapting to a virtual world. In many cases, surgeries are delayed unless they are essential. This is also true with regards to cancer treatments and screening. Interestingly, some existing drugs and nutraceuticals have been screened for their effects on COVID-19. Certain FDA approved drugs, vitamin, natural products and trace minerals may be repurposed to treat or improve the prevention of COVID-19 infections and disea…

0301 basic medicineCancer ResearchDiseaseComorbidityAntineoplastic Agent0302 clinical medicineRepurposing approved drugNeoplasmsPandemicMedicineViralCancerNatural productsVitaminsSpike GlycoproteinHost-Pathogen InteractionDrug repositioning030220 oncology & carcinogenesisHost-Pathogen InteractionsSpike Glycoprotein CoronavirusMolecular MedicineNutraceuticalAngiotensin-Converting Enzyme 2NutraceuticalsCoronavirus InfectionsHumanHydroxychloroquineSignal Transductionmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralAntineoplastic AgentsPeptidyl-Dipeptidase AAntiviral AgentsNatural productVitaminArticle03 medical and health sciencesBetacoronavirusGeneticsHumansIntensive care medicineMolecular BiologyPandemicsTrace ElementAntiviral AgentBetacoronaviruCoronavirus Infectionbusiness.industrySARS-CoV-2CanceRepurposing approved drugsDrug RepositioningrNatural productsCancerCOVID-19Pneumoniamedicine.diseaseComorbidityReview articleTrace ElementsCoronavirus030104 developmental biologyGene Expression RegulationSettore BIO/14 - FarmacologiaNeoplasmbusinessSpike Glycoprotein Coronaviru
researchProduct

Hydroxyurea‑induced superinfected ulcerations: Two case reports and review of the literature

2020

The chronic use of hydroxyurea (HU) in some oncologic and non-oncologic diseases (psoriasis, sickle cell anemia) can be accompanied by side effects, both systemic and mucocutaneous. The most severe adverse events known in HU therapy are leg ulcers and cutaneous carcinomas. At skin level may also appear: xerosis, persistent pruritus, skin color changes (erythema, hyperpigmentation), cutaneous atrophy. Likewise, oral ulcerations and stomatitis may occur at mucosal level. Hair damage can be expressed through alopecia and nail damage through melanonychia and oncycholysis. First case, a 63-year-old woman with severe psoriasis vulgaris and chronic granulocytic leukemia, with 5 years of HU therapy…

0301 basic medicineCancer Researchmedicine.medical_specialtyErythemaMucocutaneous zoneleg ulcersmedicine.disease_causehydroxyurea03 medical and health sciences0302 clinical medicineImmunology and Microbiology (miscellaneous)PsoriasismedicineStomatitiscutaneousbusiness.industrysuperinfectedArticlesGeneral Medicinemedicine.diseaseHyperpigmentationDermatologyside effects030104 developmental biologyMelanonychia030220 oncology & carcinogenesisCellulitisSuperinfectionmedicine.symptombusinessExperimental and Therapeutic Medicine
researchProduct

Le cancer du col de l’utérus : état des lieux et prévention au Maroc

2019

With more than 3300 new cases and almost 2500 deaths each year, cervical cancer (CC) ranks second among female cancers in Moroccan women. The majority of cases occurs in women aged 50 and over. In absence of a national cancer registry, data published in Morocco are limited to the number of cases recorded in some oncology centers, so the incidence of this cancer is likely much higher than estimated. A Moroccan national program against CC based on the practice of visual inspection after application of acetic acid was set up in 2010, allowing both screening and possibly immediate treatment of (pre)cancerous lesions. However, this program has not been implemented in all regions of the country. …

0301 basic medicineCancer Researchmedicine.medical_specialty[SDV]Life Sciences [q-bio]Disease03 medical and health sciencesPapillomavirus Vaccines0302 clinical medicinemedicineRadiology Nuclear Medicine and imagingGynecologyCervical cancerbusiness.industryIncidence (epidemiology)HPV infectionCancerHematologyGeneral Medicinemedicine.disease3. Good healthCancer registry030104 developmental biologyOncology030220 oncology & carcinogenesisCoinfectionbusiness
researchProduct

Should we continue to use prediction tools to identify patients at risk of Candida spp. infection? If yes, why?

2016

Background Given the predominance of invasive fungal disease (IFD) amongst the non-immunocompromised adult critically ill population, the potential benefit of antifungal prophylaxis and the lack of generalisable tools to identify high risk patients, the aim of the current study was to describe the epidemiology of IFD in UK critical care units, and to develop and validate a clinical risk prediction tool to identify non-neutropenic, critically ill adult patients at high risk of IFD who would benefit from antifungal prophylaxis. Methods Data on risk factors for, and outcomes from, IFD were collected for consecutive admissions to adult, general critical care units in the UK participating in the…

0301 basic medicineCandida spp; Invasive fungal infections; Sepsismedicine.medical_specialtyAntifungal AgentsSepsi030106 microbiologyMycoseSubgroup analysisCritical Care and Intensive Care Medicinelaw.inventionSepsis03 medical and health sciences0302 clinical medicineInvasive fungal infectionRandomized controlled trialRisk FactorsInvasive fungal infectionslawSepsisIntensive caremedicineHumansAntifungal Agent030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineCandidaCandida sppProphylaxisbusiness.industryIncidence (epidemiology)Risk FactorCandidiasismedicine.diseaseConfidence intervalCritical careFungalMycosesRelative riskCandida sppCandidiasiCandida spp; Invasive fungal infections; Sepsis; Antifungal Agents; Candida; Humans; Risk Factors; Candidiasis; Mycoses; Critical Care and Intensive Care MedicineInvasive fungal diseasebusinessResearch ArticleHuman
researchProduct

Plastic and micro-evolutionary responses of a nematode to the host immune environment

2017

9 pages; International audience; Parasitic organisms have to cope with the defences deployed by their hosts and this can be achieved adopting immune evasion strategies or optimal life history traits according to the prevailing pattern of immune-mediated mortality. Parasites often encounter variable immune environments both within and between hosts, promoting the evolution of plastic strategies instead of fixed responses. Here, we explored the plasticity and micro-evolutionary responses of immunomodulatory mechanisms and life history traits to the immune environment provided by the host, using the parasitic nematode Heligmosomoides polygyrus. To test if the parasite responds plastically to t…

0301 basic medicineCandidate genePhenotypic plasticityFecesMice0302 clinical medicine[ SDV.EE.IEO ] Life Sciences [q-bio]/Ecology environment/Symbiosis[ SDV.IMM ] Life Sciences [q-bio]/ImmunologySerial PassageMice Inbred BALB CNematospiroides dubiusGeneral MedicineDNA HelminthInfectious DiseasesCytokines[SDV.IMM]Life Sciences [q-bio]/ImmunologyMicro-evolutionFemalemedicine.symptom[ SDV.MP.PAR ] Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyDNA ComplementaryImmunologyInflammationBiologyReal-Time Polymerase Chain ReactionLife history theoryImmunomodulation03 medical and health sciencesImmune systemmedicineAnimals[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyRNA MessengerParasite Egg CountSelectionGeneStrongylida InfectionsAnalysis of VarianceHost (biology)Life history traitsbiology.organism_classification030104 developmental biologyNematodeImmunologyLinear ModelsbacteriaParasitologyGene expressionHeligmosomoides polygyrusRNA Helminth[SDV.EE.IEO]Life Sciences [q-bio]/Ecology environment/Symbiosis030215 immunologyExperimental Parasitology
researchProduct